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INTRODUCTION
Hepatitis B virus (HBV) is a DNA virus which is highly host and organ specific; to
date it has only been found to infect hepatocytes of man and of a few nonhuman pri-
mate species. Despite the continuing failure of virologists to find an in vitro system
for propagating HBV, it has been possible to gain a great deal of information about
the agent and about viral hepatitis, type B, as a result of the discovery of the Aus-
tralia antigen, now termed hepatitis B surface antigen (HB,Ag), and the recognition
of its significance (1-4). The presumptive infectious form of HBV is a 40-42-nm
particle, known as the Dane particle (5), which consists of an inner nucleocapsid
core, termed hepatitis B core antigen (HBCAg) (6), and an outer lipoprotein coat
composed of HB,Ag. The respective antibodies for the inner and outer components
of HBV are called anti-HB, and anti-HB,. In the last several years a number oftests
have been developed for detecting these antigens and antibodies (7). The most sensi-
tive methods are radioimmunoassays (RIA), which use solid phase or double anti-
body techniques for separating specifically bound from free radiolabeled proteins.
Almost as sensitive and avoiding the requirements for working with radioactive
isotopes are the following hemagglutination techniques: passive hemagglutination
(PHA) for anti-HB, detection, reversed passive hemagglutination (RPHA) for
HB,Ag detection, and immune adherence hemagglutination (IAHA) for anti-HB, de-
tection. A number of less sensitive methods, including agar gel diffusion, coun-
terelectrophoresis, complement fixation, and reversed passive latex agglutination,
are valuable for certain specific applications, but the more sensitive methods have
vastly increased our understanding of the clinical disease, epidemiology, and ap-
proaches to prevention oftype B hepatitis.
CLINICAL FEATURES
Acute HBV infection can produce a broad spectrum of clinical manifestations,
ranging from no overt disease to fulminant fatal hepatitis. The interval between ex-
posure and appearance of detectable serum HB,Ag is related to the infectivity titer
ofthe inoculum (8,9) and probably also to the routeofexposure; it may be as short as
2 or 3 weeks with very high titer inocula and as long as 3 or 4 months with low titer
inocula. Elevated serum enzymes, icterus, and other clinical signs as well as
symptoms tend to appear some days or weeks after the initial appearance ofHB,Ag;
they often appear in close proximity to peak HB,Ag levels (2,3,10). In most cases,
anti-HB, activity appears during the acute illness, while HB,Ag is still present (11).
The majority ofinfected people develop anti-HB, after HB,Ag clearance and during
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convalescence, although appearance ofthis antibody may be delayed for a number of
weeks or months after HB,Ag disappearance (12,13). A small minority ofindividuals
infected with HBV do not develop detectable levels ofHB,Ag, anti-HBc, or anti-HB,
during the acute illness or in convalescence.
The HBV carrier state, manifested by persistence of HB.Ag and anti-HB, and
absence ofdetectable anti-HB,, develops in a proportion ofinfected individuals, esti-
mated to be 5-10% ofadults infected in the United States. The carrier state may last
from a few years to the lifetime of the individual. Host-related factors which appear
to predispose to the development ofthe carrier state include infection at an early age,
mild or anicteric disease, and a depressed immune response because of underlying
disease or immunosuppressive treatment (14-19).
Observation of factors which predispose people infected with HBV to become car-
riers has led to considerable speculation regarding the role of humoral and cell-
mediated immune responses in the pathogenesis of type B hepatitis. Circulating
HB,Ag/anti-HB, complexes have been suggested as causative factors in fulminant
hepatitis and also in some of the extrahepatic manifestations of type B hepatitis,
including arthritis, urticaria, polyarteritis, and glomerulonephritis (20). Cell-
mediated immunity has been considered a possible mediator of hepatocellular
damage in acute and chronic hepatitis, and deficient cell-mediated immunity with
consequent deficient antibody production has been postulated as the underlying
defect responsible for the development ofthe carrier state (21). Direct proofofthese
hypotheses is difficult to obtain because laboratory methods for detecting cell-
mediated immunity are not as well standardized and quantitative as tests for
humoral immune responses. Consequently there is considerable variation in the
results and interpretation of tests of the cellular immune response in patients with
type B hepatitis. Nevertheless, it is likely that a better understanding of the nature
and significance of cellular immune response to HBV infection is needed to under-
stand why some people become carriers and also why there are such variegated
clinical manifestations ofacute infections as well as ofthe carrier state. In individuals
with chronic HBV infections, it is possible to have essentially no detectable liver
disease or to have complications ofincreasing severity, from chronic persistent hepa-
titis to chronic active hepatitis, macronodular cirrhosis, and primary hepatocellular
carcinoma.
There are two additional markers of HBV infection which are thought to correlate
with the amount of infectivity in serum. The first of these is the HBV-specific DNA
polymerase, described by Hirschman and by Robinson and their colleagues (22,23),
and the second is the e antigen described by Magnius and Espmark (24). Both of
these markers are present in sera containing large numbers of Dane particles, and
therefore they may well be indicators of high levels of infectivity. The nature and
source of the e antigen have not been fully clarified, but it is clear that neither de-
tectable DNA polymerase which is closely associated with HB,Ag nor detectable e
antigen is a prerequisite for infectivity for serum. Evidence has been cited in support
of the hypothesis that anti-e in HB,Ag carriers' sera is indicativeoflack ofinfectivity
of these sera, but it seems premature to judge the reliability of this marker.
However, particularly in the case of e and anti-e, it may be necessary to develop
more sensitive detection methods, as was the case for HB,Ag and anti-HB, in order
to develop a clearer picture of the prevalence and significance of these serologic
markers.
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EPIDEMIOLOGY
Extremely important and sometimes surprising insights into the epidemiology of
type B hepatitis have resulted from the application of tests for hepatitis B antigens
and antibodies. It is clear, for example, that therapeutic transfusion or injection of
blood and blood products contaminated with HBV is a relatively uncommon mode of
transmission of type B hepatitis. The early population studies by Blumberg and his
associates established that HB,Ag prevalence is much higher in developing countries
in tropical areas where therapeutic blood transfusion is uncommon than in the
United States and other western countries where treatment with blood and blood
products is much more widely practiced (25).
Probably the commonest modes of spread of type B hepatitis are from infected
mothers to infants and by members of families by close personal contact. Although
infants appear to be at highest risk when the mother experiences an acute episode of
type B hepatitis during the latter part of pregnancy, there is also ample evidence of
infection of infants whose mothers are HB,Ag carriers (14). As mentioned above, in-
fection early in life appears to be associated with an extremely high risk ofdeveloping
chronic infection.
Person-to-person spread by close contact would appear to account for the high
prevalence of HBV infection in settings such as custodial institutions for mentally
retarded patients as well as in families where one member is a carrier (15,26). Al-
though several studies have provided persuasive evidence that type B hepatitis can be
a sexually transmitted disease, the increased risk in families applies to parents, sib-
lings, and offspring as well as spouses (26-28). In view of these documented patterns
of person-to-person spread of HBV, it is probably significant that HB,Ag has been
detected in a number of body fluids other than blood, including urine, saliva, tears,
sweat, breast milk, and semen (27). The possible role ofthese body fluids in spread of
the disease and also the possibility that bloodsucking arthropods may serve the same
function as contaminated needles have been suggested but not yet definitively es-
tablished.
Further insights into the epidemiology of type B hepatitis have been provided by
the identification of four major subtypes of HB.Ag, termed adw, ayw, adr, and ayr
(29,30). Subdeterminants of the major subtypes and additional specificities are still
being discovered (31). Although there are no definite correlations between infecting
subtypes and clinical features of type B hepatitis such as severity, tendency toward
chronicity, or manifestations of chronic infections, the subtypes have proved most
useful as epidemiologic markers (32-34). In the United States and Western Europe,
the adw subtype is found in the majority of carriers and the ayw subtype in most of
the remainder, whereas in the Soviet Union and parts of Africa the ayw subtype is
predominant (31). The adr subtype is largely concentrated in Southeast Asia, and the
ayr subtype is relatively rare, only a few examples having been identified to date. It is
firmly established that the subtypes are virus-determined specificities which breed
true in infected people and experimental animals (9,34). There are also a number of
examples of individuals simultaneously infected with the adw and ayw subtypes who
produce HB,Ag with adyw specificity (32).
IMPACT OF TESTING ON TRANSFUSION THERAPY
Testing for the presence of HB,Ag in blood collected for transfusion or for further
manufacturing into plasma derivatives has become a standard procedure in many
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countries over the past 5 years. Since September 1975, blood banks in this country
have been required to test every unit collected by one of the highly sensitive, third-
generation methods (RIA or RPHA).
Since the interval between transfusion and onset of type B hepatitis may be many
months and HBV infections are often subclinical, the best means of studying the im-
pact of testing on blood safety is to follow transfused patients prospectively. Such
prospective studies provided the first unequivocal evidence of the validity of HB,Ag
as a marker for the presence of HBV, in that virtually all susceptible individuals who
received units of blood containing HB,Ag developed some evidence of exposure to
HBV (2,35-37). Over half the recipients of blood containing HB.Ag developed
enzyme changes indicative of liver damage, but a lower proportion developed overt
clinical disease. Much lower rates ofenzyme elevations and clinical disease were seen
in control groups ofpatients who were transfused with blood that was nonreactive for
HBSAg. In recent prospective studies of patients transfused with blood which has
been tested and found nonreactive by one of the most sensitive available techniques
(RIA), there is a small residue of HBV infections, presumably from units of blood
contaminated with HBV but containing too little HB.Ag for detection by present
methods (38,39).
In addition to the direct benefits ofavoiding transfusion ofunits ofHB.Ag-reactive
blood, testing has had a very significant indirect benefit by providing quantitative in-
dications of the excessively high hepatitis risk associated with blood collected from
paid donors by commercial blood banks (37,40). Earlier studies, prior to the applica-
tion of tests for HB,Ag, provided considerable evidenceof a higher risk ofhepatitis in
recipients of blood from paid donors as compared with blood from voluntary donors
(41). Prospective studies since the advent of HBsAg testing showed that a greater
effect on the safety of transfused blood would be realized by elimination of blood
from paid donors than by testing alone (42,43), and accordingly the American Blood
Commission established a goal of an all-voluntary donor system by the end of 1975.
Further effort to achieve this goal has been stimulated by an FDA proposed require-
ment that all units of blood be labeled to indicate whether they were collected from
voluntary or paid donors and, in the latter case, to indicate that blood from paid
donors carries an increased risk of transmitting viral hepatitis (44). Blood from paid
donors not only carries an increased risk of contamination with HBV but also has
been found to be associated with a markedly increased incidence of non-A, non-B
hepatitis (38,42,43,45).
Anti-HBs in donor blood does not appear to be associated with an increased risk of
infectivity. In fact, anti-HB, appears to be a better indicator of active HBV replica-
tion than anti-HBs, and therefore anti-HB, is currently being evaluated as a marker
for identifying infectious units ofblood which do not contain detectable HB.Ag (46).
Transmission of type B hepatitis by certain plasma derivatives, which are made
from pooled plasma collected by plasmapheresis, remains a serious problem, which is
not likely to be resolved by third-generation testing (47). The highest risk plasma de-
rivatives are antihemophilic factor concentrates for treatment ofhemophilia A, fac-
tor II, VII, IX, and X concentrates for treatment ofhemophilia B, and fibrinogen, for
which there appear to be few valid clinical indications. A particularly serious problem
has been the promiscuous use of factor II, VII, IX, and X concentrates as broad-
spectrum hemostatic agents in postoperative patients and patients with liver
disease. The result has been a number of clusters of type B hepatitis cases with
considerable morbidity and mortality (48,49). Experimental efforts are in progress to
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free these products of HBV by introduction ofsteps to remove or inactivate the virus,
but these efforts have met with only limited success to date. HBV removal from red
blood cells by washing, with or without a freeze-thaw cycle, is also being evaluated as
a means of improving the safety of red cell transfusions. Although washing
procedures will clearly reduce the amount of contamination of red blood cells with
HBV, it seems unlikely that complete removal of the virus will be accomplished by
this approach.
PROGRESS TOWARDS CONTROL:
PASSIVE AND ACTIVE IMMUNIZATION
Initial pilot studies of prevention of type B hepatitis with high titer hepatitis B im-
mune globulin (HBIG) gave promising results of partial effectiveness (50,51). Ac-
cordingly, a number of controlled clinical studies were undertaken in this country
and abroad (28,52-56). In all ofthese studies individuals at high risk ofacquiring type
B hepatitis due to accidental inoculation, being on the staffor being a patient in renal
dialysis units or being exposed by close contact to a spouse with acute type B hepa-
titis received either HBIG or an immune serum globulin preparation with a low level
of anti-HBS. Preliminary reports of these studies have revealed partial and tempo-
rary protection.
Development of experimental hepatitis B vaccines is in a much earlier phase of
evaluation in experimental animals using the chimpanzee model. Two groups in this
country have independently prepared experimental vaccines consisting of formalin-
treated HBsAg purified from human plasma. Preliminary reports of inoculation of
these preparations into susceptible chimpanzees have revealed no residual infectious
virus and definite protection against challenge with HBV (57, 58). Although it will un-
questionably require a great deal of painstaking effort over a number of years to
evaluate the safety and effectiveness ofexperimental hepatitis B vaccines, the partial
effectiveness, at best, ofpassive immunization and the fact that thedisease cannot be
controlled by HB.Ag testing alone make vaccine development an endeavor that de-
serves high priority in our national biomedical research and development activities.
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